Genentech Inc. came to last week’s annual cancer research meeting in Chicago like a 30-year-old tennis champ whose victories had raised the level of the game but who now faced a field of hungry young rivals.The South San Francisco biotechnology pioneer found itself eying new companies who, inspired by its example as a cancer drug developer, are trying to go one up on it.
